<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>åˆ¶è¯æ—¥æŠ¥ - 2026-01-27</title>
    <style>
        :root, [data-theme="minimal"] {
            --bg-primary: #ffffff;
            --bg-secondary: #f5f5f7;
            --text-primary: #1d1d1f;
            --text-secondary: #86868b;
            --accent: #0071e3;
            --accent-hover: #0077ed;
            --border: #d2d2d7;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.05);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        [data-theme="pharma-blue"] {
            --bg-primary: #f0f4f8;
            --bg-secondary: #ffffff;
            --text-primary: #2d3748;
            --text-secondary: #718096;
            --accent: #2b6cb0;
            --accent-hover: #2c5282;
            --border: #e2e8f0;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.1), 0 2px 4px -1px rgba(0, 0, 0, 0.06);
            --header-bg: linear-gradient(135deg, #1a365d 0%, #2b6cb0 100%);
            --header-text: #ffffff;
        }

        [data-theme="warm"] {
            --bg-primary: #faf8f5;
            --bg-secondary: #ffffff;
            --text-primary: #451a03;
            --text-secondary: #78716c;
            --accent: #d97706;
            --accent-hover: #b45309;
            --border: #e7e5e4;
            --card-shadow: 0 1px 3px 0 rgba(0, 0, 0, 0.1);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "SF Pro Display", "SF Pro Text", "Helvetica Neue", "PingFang SC", "Microsoft YaHei", sans-serif;
            background: var(--bg-primary);
            color: var(--text-primary);
            line-height: 1.5;
            -webkit-font-smoothing: antialiased;
        }

        .container {
            max-width: 980px;
            margin: 0 auto;
            padding: 0 22px;
        }

        /* Header */
        header {
            padding: 80px 0 60px;
            text-align: center;
        }

        .logo {
            font-size: 48px;
            margin-bottom: 16px;
        }

        h1 {
            font-size: 48px;
            font-weight: 600;
            letter-spacing: -0.02em;
            margin-bottom: 8px;
        }

        .subtitle {
            font-size: 21px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        /* Stats */
        .stats-bar {
            display: flex;
            justify-content: center;
            gap: 48px;
            padding: 32px 0;
            margin: 40px 0;
            border-top: 1px solid var(--border);
            border-bottom: 1px solid var(--border);
        }

        .stat {
            text-align: center;
        }

        .stat-value {
            font-size: 32px;
            font-weight: 600;
            color: var(--text-primary);
        }

        .stat-label {
            font-size: 14px;
            color: var(--text-secondary);
            margin-top: 4px;
        }

        /* Analysis Section */
        .analysis {
            background: var(--bg-secondary);
            border-radius: 18px;
            padding: 32px;
            margin-bottom: 48px;
        }

        .analysis h2 {
            font-size: 24px;
            margin-bottom: 16px;
        }

        .analysis-content {
            font-size: 17px;
            line-height: 1.7;
            color: var(--text-secondary);
        }

        /* Category Section */
        .category {
            margin-bottom: 56px;
        }

        .category-header {
            display: flex;
            align-items: baseline;
            gap: 12px;
            margin-bottom: 24px;
            padding-bottom: 12px;
            border-bottom: 1px solid var(--border);
        }

        .category-title {
            font-size: 28px;
            font-weight: 600;
        }

        .category-title-en {
            font-size: 17px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        .category-count {
            background: var(--bg-secondary);
            color: var(--text-secondary);
            padding: 4px 12px;
            border-radius: 20px;
            font-size: 14px;
            margin-left: auto;
        }

        /* News Card */
        .news-card {
            background: var(--bg-primary);
            border: 1px solid var(--border);
            border-radius: 18px;
            padding: 28px;
            margin-bottom: 16px;
            transition: all 0.3s ease;
        }

        .news-card:hover {
            box-shadow: var(--card-shadow);
            transform: translateY(-2px);
        }

        .news-card h3 {
            font-size: 21px;
            font-weight: 600;
            margin-bottom: 12px;
            line-height: 1.4;
        }

        .news-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 16px;
            margin-bottom: 16px;
            font-size: 14px;
            color: var(--text-secondary);
        }

        .news-source {
            color: var(--accent);
            font-weight: 500;
        }

        .news-importance {
            letter-spacing: 2px;
        }

        .news-summary {
            font-size: 17px;
            color: var(--text-secondary);
            line-height: 1.6;
            margin-bottom: 16px;
        }

        .news-link {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            color: var(--accent);
            text-decoration: none;
            font-size: 17px;
            font-weight: 500;
            transition: color 0.2s;
        }

        .news-link:hover {
            color: var(--accent-hover);
        }

        .news-link::after {
            content: "â†’";
            transition: transform 0.2s;
        }

        .news-link:hover::after {
            transform: translateX(4px);
        }

        /* Footer */
        footer {
            text-align: center;
            padding: 48px 0;
            color: var(--text-secondary);
            font-size: 14px;
            border-top: 1px solid var(--border);
            margin-top: 48px;
        }

        footer p {
            margin-bottom: 8px;
        }

        /* Language Flag */
        .lang-flag {
            font-size: 16px;
            margin-right: 8px;
        }

        /* Date Filter */
        .date-filter {
            display: flex;
            justify-content: center;
            gap: 8px;
            flex-wrap: wrap;
            margin-bottom: 32px;
        }

        .date-btn {
            padding: 8px 16px;
            border: 1px solid var(--border);
            border-radius: 20px;
            background: var(--bg-primary);
            color: var(--text-secondary);
            font-size: 14px;
            cursor: pointer;
            transition: all 0.2s ease;
            display: flex;
            flex-direction: column;
            align-items: center;
            min-width: 70px;
        }

        .date-btn:hover {
            border-color: var(--accent);
            color: var(--accent);
        }

        .date-btn.active {
            background: var(--accent);
            border-color: var(--accent);
            color: white;
        }

        .date-btn.weekend {
            background: var(--bg-secondary);
        }

        .date-btn.weekend.active {
            background: var(--accent);
        }

        .date-btn .weekday {
            font-size: 12px;
            opacity: 0.8;
        }

        .date-btn .date-display {
            font-weight: 500;
        }

        .filter-count {
            text-align: center;
            color: var(--text-secondary);
            font-size: 14px;
            margin-bottom: 24px;
        }

        .news-card.hidden {
            display: none;
        }

        /* Theme Switcher */
        .theme-switcher {
            position: fixed;
            top: 20px;
            right: 20px;
            display: flex;
            gap: 8px;
            background: var(--bg-secondary);
            padding: 8px;
            border-radius: 12px;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.1);
            z-index: 1000;
        }

        .theme-btn {
            width: 32px;
            height: 32px;
            border: 2px solid transparent;
            border-radius: 8px;
            cursor: pointer;
            transition: all 0.2s ease;
            position: relative;
        }

        .theme-btn:hover {
            transform: scale(1.1);
        }

        .theme-btn.active {
            border-color: var(--accent);
        }

        .theme-btn[data-theme="minimal"] {
            background: linear-gradient(135deg, #ffffff 50%, #0071e3 50%);
        }

        .theme-btn[data-theme="pharma-blue"] {
            background: linear-gradient(135deg, #1a365d 50%, #2b6cb0 50%);
        }

        .theme-btn[data-theme="warm"] {
            background: linear-gradient(135deg, #faf8f5 50%, #d97706 50%);
        }

        /* Responsive */
        @media (max-width: 734px) {
            header {
                padding: 48px 0 40px;
            }

            h1 {
                font-size: 32px;
            }

            .subtitle {
                font-size: 17px;
            }

            .stats-bar {
                gap: 24px;
            }

            .stat-value {
                font-size: 24px;
            }

            .category-title {
                font-size: 24px;
            }

            .news-card {
                padding: 20px;
            }

            .news-card h3 {
                font-size: 19px;
            }
        }
    </style>
</head>
<body>
    <!-- Theme Switcher -->
    <div class="theme-switcher">
        <button class="theme-btn active" data-theme="minimal" title="ç®€çº¦ç™½"></button>
        <button class="theme-btn" data-theme="pharma-blue" title="åŒ»è¯è“"></button>
        <button class="theme-btn" data-theme="warm" title="æš–è‰²è°ƒ"></button>
    </div>

    <div class="container">
        <header>
            <div class="logo">ğŸ’Š</div>
            <h1>åˆ¶è¯æ—¥æŠ¥</h1>
            <p class="subtitle">Pharma Daily Â· 2026-01-27 <span style="font-size: 14px; opacity: 0.7;">(US Eastern / EST)</span></p>
        </header>

        <div class="stats-bar">
            <div class="stat">
                <div class="stat-value">102</div>
                <div class="stat-label">æ–°é—»æ€»æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">4</div>
                <div class="stat-label">ç±»åˆ«æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">2026-01-28 03:45</div>
                <div class="stat-label">æ›´æ–°æ—¶é—´</div>
            </div>
        </div>

        <!-- Date Filter -->
        <div class="date-filter">
            <button class="date-btn active" data-filter="all">
                <span class="weekday">å…¨éƒ¨</span>
                <span class="date-display">All</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-21">
                <span class="weekday">å‘¨ä¸‰</span>
                <span class="date-display">01/21</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-22">
                <span class="weekday">å‘¨å››</span>
                <span class="date-display">01/22</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-23">
                <span class="weekday">å‘¨äº”</span>
                <span class="date-display">01/23</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-01-24">
                <span class="weekday">å‘¨å…­</span>
                <span class="date-display">01/24</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-01-25">
                <span class="weekday">å‘¨æ—¥</span>
                <span class="date-display">01/25</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-26">
                <span class="weekday">å‘¨ä¸€</span>
                <span class="date-display">01/26</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-27">
                <span class="weekday">å‘¨äºŒ</span>
                <span class="date-display">01/27</span>
            </button>
            
        </div>
        <div class="filter-count" id="filterCount"></div>

        
        <section class="analysis">
            <h2>ğŸ“Š ä»Šæ—¥æ¦‚è§ˆ</h2>
            <div class="analysis-content">
                <h3>ğŸ“Š AI æ™ºèƒ½åˆ†æ</h3>
<h4>ä»Šæ—¥æ¦‚è§ˆ</h4>
<p>ä»Šæ—¥åˆ¶è¯è¡Œä¸šåŠ¨æ€èšç„¦äºç›‘ç®¡å®¡æ‰¹ä¸ä¸´åºŠè¯•éªŒè¿›å±•ã€‚FDAæ‰¹å‡†äº†å¼ºç”ŸDarzalex Fasproè”åˆç–—æ³•ç”¨äºæ–°è¯Šæ–­å¤šå‘æ€§éª¨é«“ç˜¤ï¼ŒåŒæ—¶æœ‰æ¡ä»¶è§£é™¤äº†IntelliaåŸºå› ç¼–è¾‘ç–—æ³•çš„ä¸€é¡¹ä¸´åºŠæš‚åœã€‚æ­¤å¤–ï¼Œè¯ºå’Œè¯ºå¾·å£æœWegovyä¸Šå¸‚åˆæœŸè¡¨ç°å¼ºåŠ²ï¼Œè€ŒBausch Healthçš„Xifaxanåç»§è¯ç‰©IIIæœŸè¯•éªŒå¤±è´¥åˆ™å¸¦æ¥æŒ«æŠ˜ã€‚</p>
<h4>ğŸ”¥ é‡ç‚¹æ–°é—»</h4>
<p><strong>4. FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹<br>
   - FDAæ‰¹å‡†äº†å¤šå‘æ€§éª¨é«“ç˜¤ä¸€çº¿æ²»ç–—çš„é‡è¦æ–°è”åˆç–—æ³•ï¼Œå°†ç›´æ¥å½±å“ä¸´åºŠå®è·µå’Œå¸‚åœºç«äº‰æ ¼å±€ã€‚</p>
<p><strong>3. FDA lifts hold on an Intellia CRISPR drug trial</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹<br>
   - FDAè§£é™¤å¯¹Intellia CRISPRåŸºå› ç¼–è¾‘ç–—æ³•ä¸€é¡¹å…³é”®IIIæœŸè¯•éªŒçš„æš‚åœï¼Œæ˜¯åŸºå› æ²»ç–—é¢†åŸŸçš„é‡è¦ç›‘ç®¡è¿›å±•ã€‚</p>
<p><strong>11. Novo's Wegovy pill launch wows with strong early uptake: analysts</strong> â­â­â­â­<br>
   - ç±»åˆ«: å¸‚åœºåˆ†æ<br>
   - è¯ºå’Œè¯ºå¾·å£æœç‰ˆWegovyä¸Šå¸‚åˆæœŸå¤„æ–¹é‡è¡¨ç°å¼ºåŠ²ï¼Œé¢„ç¤ºç€å£æœGLP-1è¯ç‰©å¯èƒ½é‡å¡‘å·¨å¤§çš„å‡è‚¥è¯å¸‚åœºã€‚</p>
<p><strong>7. Bausch Health's $2B pursuit of Xifaxan successor hits wall with phase 3 failure</strong> â­â­â­â­<br>
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ<br>
   - Bausch Healthæ ¸å¿ƒäº§å“Xifaxançš„åç»§è¯ç‰©IIIæœŸå¤±è´¥ï¼Œå¯¹å…¶äº§å“ç®¡çº¿æ›´æ–°å’Œæœªæ¥æ”¶å…¥æ„æˆé‡å¤§æ‰“å‡»ã€‚</p>
<p><strong>2. Genmab halts enrollment for cancer drug from ProfoundBio buyout</strong> â­â­â­â­<br>
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ<br>
   - Genmabæš‚åœå…¶18äº¿ç¾å…ƒæ”¶è´­æ‰€å¾—ç™Œç—‡å€™é€‰è¯ç‰©çš„æ—©æœŸè¯•éªŒå…¥ç»„ï¼Œè¡¨æ˜èµ„äº§æ•´åˆåä¸´åºŠå¼€å‘é‡æŒ«ã€‚</p>
<h4>ğŸ“ åˆ†ç±»æ‘˜è¦</h4>
<p><strong>æ–°è¯ç ”å‘</strong> (Drug R&D): åŸºå› ç¼–è¾‘ï¼ˆIntelliaï¼‰ã€æŠ—è¡°è€åŸºå› ç–—æ³•ï¼ˆLife Biosciencesï¼‰å’Œæ–°å‹å…ç–«è¯ç‰©ï¼ˆTRex Bioï¼‰ç­‰é¢†åŸŸæœ‰ç ”å‘è¿›å±•ï¼Œä¸­å›½åœ¨æ—©æœŸè¯ç‰©ç ”å‘æ–¹é¢çš„ä¼˜åŠ¿é¢„è®¡å°†æŒç»­ã€‚<br>
<strong>ä¸´åºŠè¯•éªŒ</strong> (Clinical Trials): å…³é”®IIIæœŸè¯•éªŒç»“æœé¢‘å‡ºï¼ŒåŒ…æ‹¬Bausch Healthçš„å¤±è´¥å’ŒRoche GLP-1è¯ç‰©çš„æ–°æ•°æ®ã€‚åŒæ—¶ï¼ŒGenmabæš‚åœäº†å…¶æ”¶è´­æ‰€å¾—èµ„äº§çš„æ—©æœŸè¯•éªŒå…¥ç»„ã€‚</p>
<h4>ğŸ”® æ˜æ—¥å…³æ³¨</h4>
<p>å…³æ³¨FDA/MHRA/Health Canadaå…³äºè‰¯å¥½ä¸´åºŠå®è·µã€ç”Ÿç‰©ç­‰æ•ˆæ€§å’Œè¯ç‰©è­¦æˆ’çš„è”åˆç ”è®¨ä¼šï¼ˆ06/02/2026ï¼‰ï¼Œå…¶è®¨è®ºå†…å®¹å¯èƒ½é¢„ç¤ºæœªæ¥ç›‘ç®¡è¶‹åŠ¿ã€‚åŒæ—¶ï¼Œéœ€ç•™æ„æ¬§ç›Ÿä¸å°åº¦æ—¨åœ¨å–æ¶ˆè¯å“å‡ºå£å…³ç¨çš„è‡ªç”±è´¸æ˜“åå®šè°ˆåˆ¤è¿›å±•ï¼Œè¿™å¯èƒ½å½±å“å…¨çƒä¾›åº”é“¾æ ¼å±€ã€‚</p>
            </div>
        </section>
        

        <main>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç»¼åˆ</h2>
                    <span class="category-title-en"></span>
                    <span class="category-count">40 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Responding to tougher FDA standards, Recipharm debuts new facility for beta-lactam drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-26 09:13</span>
                        
                        <span class="news-importance">â­â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Juggling a mix of customer demand and new regulations, Recipharm has built out a new facility in Bengaluru, India, to produce nonbacterial beta-lactam tablets. By commissioning the plant, Recipharm says it has lassoed up a â€œmajor partnershipâ€ with an unnamed, â€œleading innovative biopharmaceutical companyâ€ to help produce the partner&#39;s non-bacterial beta-lactam tablets.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/fda-winds-changing-recipharm-debuts-purpose-built-plant-beta-lactam-drugs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Bausch Health&#39;s $2B pursuit of Xifaxan successor hits wall with phase 3 failure
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-23 10:08</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the companyâ€™s bread-and-butter Xifaxanâ€”a setback that leaves a $2 billion hole in its growth plan.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/bausch-healths-2b-pursuit-xifaxan-successor-hits-wall-phase-3-failure" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        EU looks to knock out pharmaceutical export tariffs in sweeping free trade pact with India
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 11:13</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Nearly two decades after the parties first floated the idea of a free trade agreement, the turbulence of the global market has prompted the European Union and India to carry their deal across the finish line.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/eu-looks-knock-out-pharmaceutical-export-tariffs-sweeping-free-trade-pact-india" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo&#39;s Wegovy pill launch wows with strong early uptake: analysts
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-23 09:42</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">In the second week of oral Wegovyâ€™s launch, which ended Jan. 16, the obesity pill logged roughly 18,400 total prescriptions, according to IMS data cited by Jefferies. That performance is a fair bit better than that of either injectable Wegovy or Eli Lilly&#39;s Zepbound during the first two weeks of their respective rollouts, the analyst team noted.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/novos-impressive-wegovy-pill-launch-headline-and-itself-evercore-says" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Fierce Pharma Asiaâ€”Astellas CEO&#39;s BD plan; Takeda&#39;s US layoffs; Chugai&#39;s chase for name recognition
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-22 15:31</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Astellas CEO said he doesn&#39;t want to make acquisitions simply to fill a revenue gap. Takeda is preparing for Trintellix&#39;s U.S. patent expiry with a round of layoffs. Chugai&#39;s CEO is seeking name recognition as the Roche unit looks for more external partners. And more.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/astellas-ceo-bd-plan-takeda-us-layoffs-chugai-chase-name-recognition" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Biosimilar execs optimistic about future for US biosims as Sandoz locks in on &#39;golden decade&#39; to come
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-21 17:07</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Executives from top U.S. biosimilar makers are optimistic about the future of U.S. biosimilar adoption as recent FDA guidance seeks to streamline biosimilar development and potentially dissipate the upcoming â€œbiosimilar void.â€</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/biosimilar-execs-remain-optimistic-state-us-biosimilars-while-sandoz-locks-golden-decade" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about pharma lobbying, an FDA gene-editing pathway, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-26 14:05</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The pharmaceutical industry, long one of the most powerful lobbies in Washington, is spending more than ever to influence the nationâ€™s capital</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/26/pharma-lobbying-novo-genes-fda-patents/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about drug shortages, llama antibodies for developing meds, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-23 14:27</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower than the all-time high reached in 2024</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/23/moderna-vaccines-cigna-shortages-cancer-obesity-weight/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: The number of new drug shortages in U.S. hits lowest level in 20 years, but myriad problems remain
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 17:40</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower than the all-time high reached in the beginning of 2024.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/22/medicines-pharma-biotech-shortages-hospitals-injectables/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about Canada speeding drug reviews, Novo Nordisk ads, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-21 14:14</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Health Canada is planning to speed up reviews of some drugs by piggybacking on the decisions of foreign regulators, including possibly the U.S. FDA</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/21/canada-vaccines-novo-eczema-diabetes/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Teva taps â€˜SNLâ€™ alum Will Forte to join Huntingtonâ€™s disease awareness push
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-26 15:42</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Following in the footsteps of Phathom Pharmaceuticals&#39; and Allergan Aestheticsâ€™ own partnerships with â€œSaturday Night Liveâ€ stars, Teva Pharmaceuticals is turning to a famous funnyman to tackle a not-so-funny topic.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/teva-taps-snl-alum-will-forte-join-huntingtons-disease-awareness-push" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Arcutis, Kowa part ways on US marketing partnership for Zoryve
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-26 11:15</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The companies had committed to a five-year partnership in July 2024, in which Kowa agreed to promote the topical treatment to primary care physicians to extend the med&#39;s reach beyond dermatologists.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/arcutis-kowa-cut-ties-two-years-us-marketing-partnership-arcutis-topical-zorvye" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-23 11:55</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area.</p>
                    
                    <a href="https://www.fiercepharma.com/biotech/anti-vaccine-sentiment-pushes-moderna-away-new-late-stage-infectious-disease-trials" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about a Roche obesity drug, a clash over 340B claims data, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-27 14:17</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after the drug led to significant weight loss in a mid-stage trial</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/27/roche-obesity-menopause-china-lilly-340b-hospitals-bausch/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Trump administration rolls out 15 more high-profile drugs for IRA price negotiations
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 17:14</span>
                        
                    </div>
                    
                    <p class="news-summary">Even as the Trump administration works to implement its &#34;most favored nation&#34; pricing system, the U.S. government continues to advance efforts to negotiate Medicare drug prices as enabled by the Inflation Reduction Act.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/trump-administration-rolls-out-15-more-high-profile-drugs-ira-price-negotiations" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        China regulators suspend sale of Sun Pharma&#39;s dementia med after site inspection
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 11:13</span>
                        
                    </div>
                    
                    <p class="news-summary">Chinaâ€™s National Medical Products Administration suspended the import, sale and use of Sun&#39;s rivastigmine hydrogen tartrate capsules after a virtual site inspection uncovered manufacturing shortfalls.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/chinese-regulators-suspend-sale-sun-pharmas-dementia-med-after-site-inspection" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Servier delivers 16% revenue jump, firming up â‚¬10B ambition by 2030
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 10:09</span>
                        
                    </div>
                    
                    <p class="news-summary">After posting 16.2% revenue growth in the last financial year, Servier President Olivier Laureau said the company has moved â€œone important step closerâ€ to achieving an ambitious goal for 2030.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/servier-delivers-16-revenue-jump-firming-eu10b-ambition-2030" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Pfizer retains top spot in vaccine maker rankings as Sanofi&#39;s slide sparks &#39;code red&#39; call
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 10:06</span>
                        
                    </div>
                    
                    <p class="news-summary">Pfizer again heads up a physician ranking of vaccine manufacturers, beating Merck &amp;amp; Co. and Moderna to complete an unchanged top three from the last edition of the survey. But while the rankings held steady, the operating environment has changed quickly to reinforce the value of being in good standing with physicians.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/pfizer-retains-top-spot-vaccine-rankings-sanofis-slide-sparks-code-red-call" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Siegfried extends M&amp;amp;A streak, gaining 3 sites from SK Capital and advancing US onshoring aims
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 09:47</span>
                        
                    </div>
                    
                    <p class="news-summary">Siegfried has signed agreements to acquire the controlled drug substance businesses of the Noramco Group and Extractas Bioscience. With the deals, Siegfried gains API sites in Wilmington, Delaware; Athens, Georgia; and Australia.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/siegfried-continues-its-ma-splurge-gaining-3-sites-sk-capital" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Catalent moves to wind down operations at EU cell therapy manufacturing hub
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-26 15:01</span>
                        
                    </div>
                    
                    <p class="news-summary">Catalent made a series of deals early this decade to build up its presence in Gosselies. Now, it&#39;s planning to wind down cell therapy manufacturing operations in the town.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/catalent-moves-wind-down-operations-eu-cell-therapy-manufacturing-hub" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        New rules, higher stakes: Biopharma plays the long game in 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-26 13:20</span>
                        
                    </div>
                    
                    <p class="news-summary">While 2025 was dedicated to â€œunderstanding a little bit more about the rules of this game that weâ€™re playing,â€ 2026 is all about being active players in the game, McKinsey senior partner Greg Graves said Jan. 13 at Fierce JPM Week.</p>
                    
                    <a href="https://www.fiercepharma.com/biotech/new-rules-higher-stakes-biopharma-plays-long-game-2026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Daiichi Sankyo navigates complexity of success as Enhertu, Datroway push for market dominance
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-26 10:28</span>
                        
                    </div>
                    
                    <p class="news-summary">With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug conjugates. But the road to market leadership is growing more complex as the two AstraZeneca-partnered brands move into earlier lines of therapy while facing intensifying competition.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/daiichi-sankyo-navigates-complexity-success-enhertu-datroway-push-market-dominance" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Lilly battles weight stigma in short film centering obesity conversation on health, not appearance
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-23 11:52</span>
                        
                    </div>
                    
                    <p class="news-summary">GLP-1 giant Eli Lilly has once again taken to the medium of short film to get an important message about obesity across.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/lilly-battles-weight-stigma-short-film-centering-obesity-conversation-health-not" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        RFK Jr.&#39;s new ACIP chair stresses &#39;individual autonomy,&#39; questions polio shot guidance on podcast
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-23 10:19</span>
                        
                    </div>
                    
                    <p class="news-summary">The new chairman of the CDC&#39;s Advisory Committee on Immunization Practices, Kirk Milhoan, M.D., Ph.D., recently took to the podcast â€œWhy Should I Trust You?â€ to answer exactly that.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/new-acip-chair-talks-established-science-polio-vaccine-uncertainty-and-individual-autonomy" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ST Pharm inks $56M deal to produce API for a US biotech
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-23 10:15</span>
                        
                    </div>
                    
                    <p class="news-summary">ST Pharm has struck a $56 million deal with an undisclosed U.S.-based biotech to produce active pharmaceutical ingredients (APIs) for a new oligonucleotide treatment. The Korean CDMO revealed the contract Friday in a regulatory filing.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/st-pharm-inks-56m-deal-produce-apis-us-biotech" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Ocular drafts Eylea launch architect to lead attack on Regeneron&#39;s blockbuster
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-23 07:18</span>
                        
                    </div>
                    
                    <p class="news-summary">Plotting a challenge to Regeneronâ€™s blockbuster Eylea, Ocular Therapeutix has hired â€œa key architectâ€ of its rivalâ€™s launch to head its commercial team.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/ocular-drafts-eylea-launch-architect-lead-attack-regenerons-blockbuster" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        JPM26: Sunshine, AI and the deals that weren&#39;t
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-22 10:09</span>
                        
                    </div>
                    
                    <p class="news-summary">Fierceâ€™s Zoey Becker, Angus Liu and Gabrielle Masson unpack the key topics and trends that stood out at this yearâ€™s J.P. Morgan Healthcare Conference.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/recapping-2026-jp-morgan-healthcare-conference" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Global pharma manufacturing output surged in &#39;25 in &#39;front-loading&#39; response to US tariff threats: report
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-22 15:19</span>
                        
                    </div>
                    
                    <p class="news-summary">While the threat of U.S. import tariffs prompted a surge in drug production last year, that output is slated to slow across multiple geographies in 2026, according to a new report from financial services firm Atradius.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/pharma-manufacturing-output-surged-25-countries-braced-us-tariffs-atradius" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Invivyd teams up with Olympic skier Lindsey Vonn for antibody education
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-22 10:54</span>
                        
                    </div>
                    
                    <p class="news-summary">As Lindsey Vonnâ€™s comeback run heads toward a peak with Team USA at the upcoming 2026 Winter Olympics, Invivyd is adding the professional skier to its team, too.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/invivyd-teams-olympic-skier-lindsey-vonn-antibody-education" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: New startup to develop a GLP-1 drug for addiction
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-27 14:40</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news brought to you by The Readout newsletter</p>
                    
                    <a href="https://www.statnews.com/2026/01/27/biotech-news-glp-1-drug-for-addiction-startup/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Roche moves obesity drug to pivotal trials after mid-stage success
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-27 08:08</span>
                        
                    </div>
                    
                    <p class="news-summary">Roche plans to launch pivotal studies of an experimental weight loss drug after a successful mid-stage trial.</p>
                    
                    <a href="https://www.statnews.com/2026/01/27/roche-ct388-trials-weight-loss-obesity/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Hospital group wants Trump administration to block a new Lilly policy on 340B claims data
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-26 21:11</span>
                        
                    </div>
                    
                    <p class="news-summary">The American Hospital Association is asking the Trump administration to stop Eli Lilly from enacting a new policy as part of the 340B drug discount program.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/26/pharma-lilly-medicines-hospitals-340b/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Launch of Wegovy pill looks to be going strong so far
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-26 14:30</span>
                        
                    </div>
                    
                    <p class="news-summary">And more biotech news brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/01/26/biotech-news-wegovy-pill-launch-holds-promise-novo-nordisk/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Up and down the ladder: The latest comings and goings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-23 17:19</span>
                        
                    </div>
                    
                    <p class="news-summary">From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/23/pharma-biotech-jobs-teva-novartis-novo-lilly/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Insurers blame drugmakers, hospitals for high prices
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-23 15:26</span>
                        
                    </div>
                    
                    <p class="news-summary">Plus more biotech news updates, brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/01/23/biotech-news-insurers-blame-drugmakers-hospitals-for-prices/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Health insurance execs shift blame for costly, confusing health care system
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 20:11</span>
                        
                    </div>
                    
                    <p class="news-summary">Health insurance execs blame the high cost of health care on hospitals, doctors, and prescription drugs.</p>
                    
                    <a href="https://www.statnews.com/2026/01/22/health-insurance-execs-blame-high-costs-hospitals-doctors-pharma/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: France rebuffs Trump over drug-pricing boast
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 15:58</span>
                        
                    </div>
                    
                    <p class="news-summary">And more biotech news from The Readout newsletter</p>
                    
                    <a href="https://www.statnews.com/2026/01/22/biotech-news-2/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about Europeâ€™s pharma supply chain, stopping GLP-1 drugs, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 14:26</span>
                        
                    </div>
                    
                    <p class="news-summary">Many patients using GLP-1 drugs like Wegovy may not regain lost weight quickly when they stop treatment, an analysis of real-world data shows</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/22/europe-insulin-novo-weight-cvs-pharmacies/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Anthony Letai says NCI is more stable than perceived and is heading for a big year
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Anthony Letai says the National Cancer Institute is more stable than perceived and is heading for a big year.</p>
                    
                    <a href="https://www.statnews.com/2026/01/22/national-cancer-institute-director-anthony-letai-q-and-a/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Novo strikes deal for diabetes cell therapies
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-21 14:53</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news, brought to you by The Readout newsletter</p>
                    
                    <a href="https://www.statnews.com/2026/01/21/biotech-news-novo-nordisk-acquires-aspect-biosystems/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">æ–°è¯ç ”å‘</h2>
                    <span class="category-title-en">Drug R&amp;D</span>
                    <span class="category-count">34 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Genmab halts enrollment for cancer drug from ProfoundBio buyout
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-26 11:31</span>
                        
                        <span class="news-importance">â­â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Genmab has stopped enrolling patients for an early-stage trial of a cancer candidate it obtained in its $1.8 billion acquisition of US-China biotech ProfoundBio. The Phase 1/2 study of GEN1286 was meant to enroll 260 ...</p>
                    
                    <a href="https://endpoints.news/genmab-halts-enrollment-for-cancer-drug-from-profoundbio-buyout/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA lifts hold on an Intellia CRISPR drug trial
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-27 16:59</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in people with transthyretin amyloidosis. One of those tests remains suspended.</p>
                    
                    <a href="https://www.biopharmadive.com/news/intellia-fda-lifts-hold-nex-z-crispr-ttr-amyloidosis/810584/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA lifts hold on one of two Phase 3 gene editing studies by Intellia
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 15:52</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The FDA has allowed Intellia Therapeutics to resume one of its two pivotal trials of a gene editing therapy for transthyretin amyloidosis, which is a disease caused by misfolded proteins. Intellia</p>
                    
                    <a href="https://endpoints.news/fda-lifts-hold-on-one-of-two-phase-3-gene-editing-studies-by-intellia/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Roche, trailing in obesity, showcases new data for GLP-1 shot
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-27 16:31</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts said.</p>
                    
                    <a href="https://www.biopharmadive.com/news/roche-obesity-drug-phase-2-data-carmot-glp-gip/810578/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        An immune drug developer raises $50M to finance its eczema drug testing
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-27 15:53</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.</p>
                    
                    <a href="https://www.biopharmadive.com/news/trex-bio-series-b-extension-atopic-dermatitis/810617/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Chinaâ€™s edge in early-stage drugmaking â€˜likely to persist,â€™ Pitchbook says
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-26 19:15</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The ongoing surge in licensing deals for early drug prospects should continue this year and involve more cell and gene therapies, which have had trouble securing funding in the U.S., the firm said in a new report.</p>
                    
                    <a href="https://www.biopharmadive.com/news/china-biotech-drug-licensing-trends-pitchbook-cell-gene-therapy/810478/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Biotech investor Cormorant secures $150M for another SPAC deal
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-26 14:43</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Amid a rebound in SPAC activity, the prolific &amp;ldquo;crossover&amp;rdquo; investor is aiming for its third blank-check merger since 2022 following deals with Moonlake Immunotherapeutics and BridgeBio Oncology Therapeutics.</p>
                    
                    <a href="https://www.biopharmadive.com/news/cormorant-helix-iii-spac-deal-biotech-merger-ipo/810436/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        The formula for biotech success in 2026: Confidence, resilience and funding
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-26 14:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Survey of 260+ biotech leaders assesses the biotech climate, trends, opportunities and risks.</p>
                    
                    <a href="https://www.biopharmadive.com/spons/the-formula-for-biotech-success-in-2026-confidence-resilience-and-funding/810037/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA greenlights Life Biosciences&#39; gene therapy study to rewind the age of cells
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 13:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">One of the biggest theories about the cause of aging, and how to slow and potentially even reverse it, is about to be put to the test. Life Biosciences, a biotech startup co-founded by Harvard ...</p>
                    
                    <a href="https://endpoints.news/exclusive-fda-greenlights-gene-therapy-study-to-rewind-the-age-of-cells/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        UK-US biotech investor Epidarex raises $145M for fourth fund
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 07:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Epidarex Capital raised $145 million in the first close of its fourth fund as the biotech investor searches for the next generation of standout science in overlooked research corridors of the UK and US. ...</p>
                    
                    <a href="https://endpoints.news/uk-us-biotech-investor-epidarex-raises-145m-for-fourth-fund/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-24">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        First-movers respond to herding; BioMarin vets start new biotech; GSK buys RAPT Therapeutics; and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-24 11:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Welcome back to another edition of Endpoints Weekly. Though we may have had a short week with Martin Luther King Jr. Day, the news kept on coming. Letâ€™s dive in. We had a little bit ...</p>
                    
                    <a href="https://endpoints.news/first-movers-respond-to-herding-biomarin-vets-start-new-biotech-gsk-buys-rapt-therapeutics-and-more/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ACIP members depict diverging goals after schedule change
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-23 18:24</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Fresh off health officialsâ€™ sweeping remake of the US childhood vaccine schedule, two members of a key CDC panel are depicting different versions of the committeeâ€™s work moving forward. Comments made this week by Robert ...</p>
                    
                    <a href="https://endpoints.news/acip-members-depict-diverging-goals-after-schedule-change/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Cardiff execs depart as company drops mixed Phase 2 data
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 18:22</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Shares {$CRDF} of Cardiff Oncology fell more than 30% after the biotech disclosed mixed Phase 2 data and announced the departure of two of its top executives. San Diego-based Cardiff</p>
                    
                    <a href="https://endpoints.news/cardiff-execs-depart-as-company-drops-mixed-phase-2-data/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Insilicoâ€™s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 15:40</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Insilico Medicine is having quite a month. Fresh from deals with Servier and Hygtia Therapeutics, the biotech has signed a new collaboration with Shanghai-based Qilu Pharmaceutical worth nearly ...</p>
                    
                    <a href="https://endpoints.news/insilicos-latest-deal-is-a-120m-cardiometabolic-drug-discovery-pact-with-qilu-pharma/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AstraZeneca ends work on cardio drug; Lisata and Qilu terminate deal
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 14:31</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Plus, news about Vial, Skyhawk and Gimv: AstraZeneca stops cardio drug: The UK pharma giant has terminated a Phase 1 of an oral cardio drug candidate called AZD0233, according ...</p>
                    
                    <a href="https://endpoints.news/astrazeneca-ends-work-on-cardio-drug-lisata-and-qilu-terminate-deal/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Boehringer Ingelheim gets an IBD bispecific from Shanghai-based Simcere
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 13:56</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Boehringer Ingelheim will pair up with Simcere Pharmaceutical in one of the hottest targets in immunology. For â‚¬42 million ($50 million) upfront, the German pharma will tap into Simcere&#39;s preclinical TL1AxIL-23p19 bispecific antibody for inflammatory ...</p>
                    
                    <a href="https://endpoints.news/boehringer-ingelheim-gets-an-ibd-bispecific-from-shanghai-based-simcere/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Updated: Rocheâ€™s obesity shot posts decent weight loss in mid-stage test, heads to Phase 3
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 12:09</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Rocheâ€™s most advanced obesity drug allowed patients in a Phase 2 trial who took it for nearly a year to lose 18.3% of their weight after correcting for placebo, the Swiss pharma said Tuesday. ...</p>
                    
                    <a href="https://endpoints.news/roches-obesity-shot-posts-decent-weight-loss-in-mid-stage-test-heads-to-phase-3/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        TRexBio gets another $50M to bring more Treg candidates into the clinic
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 12:00</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Bay Area startup TRexBio has bolstered its 2024 Series B with an additional $50 million to fund the biotech&#39;s clinical development in the burgeoning Treg space. The biotech, founded in 2018 by SV Health Investors ...</p>
                    
                    <a href="https://endpoints.news/trexbio-gets-another-50m-to-bring-more-treg-candidates-into-the-clinic/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sarepta touts three-year Duchenne gene therapy data after patient deaths
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-26 16:17</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Sarepta said the effects of its Duchenne muscular dystrophy gene therapy were durable three years after treatment, based on longer-term findings from patients in its key clinical trial. The data come after a tumultuous year ...</p>
                    
                    <a href="https://endpoints.news/sarepta-touts-three-year-duchenne-gene-therapy-data-after-patient-deaths/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        EU kicks off one-year pilot to expedite multinational trials
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-23 19:24</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The European Union unveiled details of a pilot project that aims to accelerate the timeline for starting new multinational clinical trials. The voluntary pilot, called FASTâ€‘EU, will feature a maximum 10â€‘week (70â€‘day) timeline from drugmaker ...</p>
                    
                    <a href="https://endpoints.news/eu-kicks-off-one-year-pilot-to-expedite-multinational-trials/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sarepta, battling slowing sales, claims Duchenne gene therapyâ€™s impact grows with time
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-26 16:46</span>
                        
                    </div>
                    
                    <p class="news-summary">On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help &amp;ldquo;rebalance the discussion&amp;rdquo; surrounding Elevidys.</p>
                    
                    <a href="https://www.biopharmadive.com/news/sarepta-elevidys-duchenne-gene-therapy-embark-data/810461/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Express Scripts considering settlement in FTC insulin price lawsuit
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-26 14:02</span>
                        
                    </div>
                    
                    <p class="news-summary">The antitrust agency paused its lawsuit against the pharmacy benefit manager while the two discuss a proposed consent agreement.</p>
                    
                    <a href="https://www.biopharmadive.com/news/cigna-express-scripts-ftc-insulin-pricing-settlement-talks/810452/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        The crucial role of raw material selection for success in cell therapy manufacturing
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-26 10:00</span>
                        
                    </div>
                    
                    <p class="news-summary">&amp;nbsp;Why raw materials make or break cell therapy manufacturing success.</p>
                    
                    <a href="https://www.biopharmadive.com/spons/the-crucial-role-of-raw-material-selection-for-success-in-cell-therapy-manu/810179/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        From detection to prevention: How sponsored testing can transform patient outcomes
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-26 10:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Diagnostic testing has long laid the groundwork for medical decision-making. &amp;nbsp;</p>
                    
                    <a href="https://www.biopharmadive.com/spons/from-detection-to-prevention-how-sponsored-testing-can-transform-patient-o/809935/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Updated: CMS picks Lillyâ€™s Trulicity, Gilead&#39;s Biktarvy for third round of Medicare negotiations
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 22:26</span>
                        
                    </div>
                    
                    <p class="news-summary">Another GLP-1 drug is up for Medicare negotiations under the Inflation Reduction Act. Eli Lillyâ€™s diabetes drug Trulicity is among 15 drugs selected for the third round of negotiations. For the ...</p>
                    
                    <a href="https://endpoints.news/cms-picks-lillys-trulicity-for-third-round-of-medicare-negotiations/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Hospitals could earn more for buying US-made drugs, CMS proposes
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 20:05</span>
                        
                    </div>
                    
                    <p class="news-summary">The Trump administration&#39;s Centers for Medicare &amp;amp; Medicaid Services is looking to incentivize hospitals to buy more domestically-produced drugs. Under a proposed rule, hospitals purchasing more than 50% of domestic-made essential ...</p>
                    
                    <a href="https://endpoints.news/hospitals-could-earn-more-for-buying-us-made-drugs-cms-proposes/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        UnitedHealth projects lower revenue in 2026 as it resets its business
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 18:11</span>
                        
                    </div>
                    
                    <p class="news-summary">UnitedHealth Groupâ€™s turnaround plan to trade membership for improved profit margins will result in lower revenue in 2026, as the healthcare giant attempts to recover from a disastrous period of setbacks that ...</p>
                    
                    <a href="https://endpoints.news/unitedhealth-projects-lower-revenue-in-2026-as-it-resets-its-business/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Virtual womenâ€™s health company Wisp buys TBD Health
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 14:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Wisp, a womenâ€™s telehealth company, bought sexual healthcare startup TBD Health, as virtual care companies look to become more comprehensive in the services they offer. Terms of the deal, which closed near ...</p>
                    
                    <a href="https://endpoints.news/virtual-womens-health-company-wisp-buys-tbd-health/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        IRA drug pricing petitions pile up at the Supreme Court
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-26 20:21</span>
                        
                    </div>
                    
                    <p class="news-summary">Novartis is now the sixth drugmaker to bring its Inflation Reduction Act challenge to the Supreme Court as the pharma industryâ€™s yearslong court battle comes to a head. Novartis was the last drugmaker expected to ...</p>
                    
                    <a href="https://endpoints.news/ira-drug-pricing-petitions-pile-up-at-the-supreme-court/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Ex-CytoDyn CEO sentenced to 30 months for pump-and-dump scheme
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-26 18:32</span>
                        
                    </div>
                    
                    <p class="news-summary">CytoDyn&#39;s former CEO Nader Pourhassan was sentenced Friday to 30 months in prison for misleading investors about the prospects of a potential drug and then selling his personal stock in the company at artificially inflated ...</p>
                    
                    <a href="https://endpoints.news/ex-cytodyn-ceo-sentenced-to-30-months-for-pump-and-dump-scheme/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Catalent plans to close Belgium cell therapy site
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-26 17:45</span>
                        
                    </div>
                    
                    <p class="news-summary">Catalent plans to close a cell therapy site in Gosselies, Belgium, due to â€œchanging market dynamics and customer needs,â€ a company spokesperson confirmed to Endpoints News. The contract developer and manufacturer is considering transitioning ...</p>
                    
                    <a href="https://endpoints.news/catalent-plans-to-close-belgium-cell-therapy-site/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Genyro licences DNA builder from Caltech; Dizal targets Hong Kong listing
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-26 15:07</span>
                        
                    </div>
                    
                    <p class="news-summary">Plus, news about United Therapeutics and Fortitude Biomedicines: ğŸ—ï¸ San Diego startup licenses &#39;DNA construction&#39; tech: Genyro gets exclusive rights to the technology, dubbed â€œSidewinder,â€ which was developed by researchers at ...</p>
                    
                    <a href="https://endpoints.news/genyro-licences-dna-builder-from-caltech-dizal-targets-hong-kong-listing/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        UK medicines agency seized 20M illegal drugs last year, including GLP-1s
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-26 12:13</span>
                        
                    </div>
                    
                    <p class="news-summary">The UKâ€™s Medicines and Healthcare products Regulatory Agency (MHRA) seized almost 20 million doses of illegally traded medicines with an estimated value of nearly Â£45 million (about $61.5 million) in 2025. This is an increase ...</p>
                    
                    <a href="https://endpoints.news/uk-medicines-agency-seized-20-million-illegal-drugs-last-year-including-glp-1s/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo&#39;s Wegovy pill off to a solid start after just two weeks on market
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-23 20:23</span>
                        
                    </div>
                    
                    <p class="news-summary">Novo Nordiskâ€™s weight loss pill is off to an impressive start after less than three weeks on the market. Prescriptions are quickly ramping up, increasing by roughly 500% in the pillâ€™s second week, analysts said ...</p>
                    
                    <a href="https://endpoints.news/novos-wegovy-pill-off-to-a-solid-start-after-just-two-weeks-on-market/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç›‘ç®¡å®¡æ‰¹</h2>
                    <span class="category-title-en">Regulatory</span>
                    <span class="category-count">20 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 19:37</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cel</p>
                    
                    <a href="http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Oncology (Cancer)/Hematologic Malignancies Approval Notifications
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 17:55</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA does not&amp;nbsp;issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to&amp;nbsp;Drugs@FDA&amp;nbsp;for the latest approvals and prescribing information for specific products.</p>
                    
                    <a href="http://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Natural Disaster Preparedness and Response | Drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-26 14:25</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Stay informed on FDA&#39;s guidance for drugs used in natural disaster preparedness and response. Learn about emergency drug supplies, FDA-approved treatments, and safety measures for public health during disasters like hurricanes, floods, and more.</p>
                    
                    <a href="http://www.fda.gov/drugs/emergency-preparedness-drugs/natural-disaster-preparedness-and-response-drugs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA/MHRA/Health Canada Symposium: Regulatory perspectives in good clinical practice, bioequivalence and good pharmacovigilance practice - 06/02/2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-26 15:26</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">This symposium will highlight current and emerging topics of interest to the industry related to good clinical practice, bioequivalence and good pharmacovigilance practice.</p>
                    
                    <a href="http://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/fdamhrahealth-canada-symposium-regulatory-perspectives-good-clinical-practice-bioequivalence-and" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Untitled Letters
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 20:21</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">These letters are supplied by the CDER Freedom of Information Office and only cover Office of Prescription Drug Promotion&#39;s untitled letters. FDA may have redacted or edited some of the letters to remove confidential information.</p>
                    
                    <a href="http://www.fda.gov/drugs/warning-letters-and-notice-violation-letters-pharmaceutical-companies/untitled-letters" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Project Orbis
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 20:13</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Information Project Orbis, an initiative of the FDA Oncology Center of Excellence (OCE) that provides a framework for concurrent submission and review of oncology products among international partners.</p>
                    
                    <a href="http://www.fda.gov/about-fda/oncology-center-excellence/project-orbis" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        What Does FDA Approve? Part 2
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 19:23</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The growing spread of rumors, misinformation and disinformation about science, medicine, and the FDA, is putting patients and consumers at risk. FDA is here to provide the facts.</p>
                    
                    <a href="http://www.fda.gov/consumers/consumer-updates/what-does-fda-approve-part-2" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        What&#39;s New Related to Drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 17:56</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Want to know what&#39;s new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.</p>
                    
                    <a href="http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drugs@FDA Data Files
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 12:35</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Patient Listening Session Summaries
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-26 21:44</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Patient Listening Session summaries are published after each session to share a high-level summary of the discussion. The Public Engagement Staff draft summaries for FDA-requested sessions and the patient community requester drafts summaries for Patient-led sessions.</p>
                    
                    <a href="http://www.fda.gov/patients/fda-patient-listening-sessions/patient-listening-session-summaries" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drugs Program Monthly and Quarterly Activities Report
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-26 18:25</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Monthly and quarterly metrics of the FDA Generic Drugs Program.</p>
                    
                    <a href="http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drugs-program-monthly-and-quarterly-activities-report" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Biosimilar Product Information
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-26 18:16</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">This page includes a chart of the approved biosimilar and interchangeable products. The approval of biosimilar products can improve access to care for patients by increasing the number of medication options and potentially lower costs.</p>
                    
                    <a href="http://www.fda.gov/drugs/biosimilars/biosimilar-product-information" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-26 15:06</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">This guidance is the third in a series of four methodological patient-focused drug development guidances that describe how stakeholders can collect and submit patient experience data and other relevant information from patients and caregivers to be used for product development decision-making.</p>
                    
                    <a href="http://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-26 15:04</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">This draft guidance provides guidance to sponsors and applicants submitting investigational new drug applications (INDs), new drug applications (NDAs), biologics licensing applications (BLAs), or supplemental applications on the appropriate use of Bayesian methods in clinical trials.</p>
                    
                    <a href="http://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-bayesian-methodology-clinical-trials-drug-and-biological-products" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Patent Certifications and Suitability Petitions
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 19:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Information on patents and suitability petitions that impact the availability of generic drugs.</p>
                    
                    <a href="http://www.fda.gov/drugs/abbreviated-new-drug-application-anda/patent-certifications-and-suitability-petitions" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug Facilities, Sites and Organization Lists
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 17:25</span>
                        
                    </div>
                    
                    <p class="news-summary">Generic Drug Facilities, Sites and Organization Lists</p>
                    
                    <a href="http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug User Fee Amendments
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 17:22</span>
                        
                    </div>
                    
                    <p class="news-summary">This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.</p>
                    
                    <a href="http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Center For Immunology Science, LLC - 719933 - 01/13/2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 14:20</span>
                        
                    </div>
                    
                    <p class="news-summary">Sponsor/Investigator</p>
                    
                    <a href="http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/center-immunology-science-llc-719933-01132026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Fulijaya Manufacturing SDN. BHD. - 719172 - 01/14/2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 14:20</span>
                        
                    </div>
                    
                    <p class="news-summary">CGMP/Finished Pharmaceuticals/Adulterated</p>
                    
                    <a href="http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fulijaya-manufacturing-sdn-bhd-719172-01142026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Genetic Metabolic Diseases Advisory Committee (GeMDAC) Charter
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-23 21:18</span>
                        
                    </div>
                    
                    <p class="news-summary">The Genetic Metabolic Diseases Advisory Committee (GeMDAC) advises the Commissioner of Food and Drugs or designee in discharging responsibilities as they relate to helping to ensure safe and effective drugs and biologic products for human use and as required.</p>
                    
                    <a href="http://www.fda.gov/advisory-committees/genetic-metabolic-diseases-advisory-committee/genetic-metabolic-diseases-advisory-committee-gemdac-charter" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">å•†ä¸šåŠ¨æ€</h2>
                    <span class="category-title-en">Business/M&amp;A</span>
                    <span class="category-count">8 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Otsuka Pharmaceuticalâ€™s Dawnzera receives EC approval for hereditary angioedema prevention
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-26 12:05</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Dawnzera showed an 81% reduction in the four-weekly rate of HAE attacks compared to placebo</p>
                    
                    <a href="https://pharmatimes.com/news/otsuka-pharmaceuticals-dawnzera-receives-ec-approval-for-hereditary-angioedema-prevention/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ErVimmune raises 17m euros in funding to develop cancer vaccine
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-22 14:10</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The vaccine could be created as a ready-to-use product, rather than needing to be personalised</p>
                    
                    <a href="https://pharmatimes.com/news/ervimmune-raises-17m-euros-in-funding-to-develop-cancer-vaccine/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        BioMed X launches kidney disease project in partnership with the government of Barbados
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-27 13:54</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Initiative focuses on population-specific molecular profiling</p>
                    
                    <a href="https://pharmatimes.com/news/biomed-x-launches-kidney-disease-project-in-partnership-with-the-government-of-barbados/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Gedeon Richter UK takes over UK rights to cariprazine
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-27 13:47</span>
                        
                    </div>
                    
                    <p class="news-summary">Company strengthens its neuropsychiatry portfolio after marketing transfer from Recordati</p>
                    
                    <a href="https://pharmatimes.com/news/gedeon-richter-uk-takes-over-uk-rights-to-cariprazine/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Corcept Therapeuticsâ€™ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-26 11:57</span>
                        
                    </div>
                    
                    <p class="news-summary">Ovarian cancer is the fifth leading cause of deaths from cancer in women</p>
                    
                    <a href="https://pharmatimes.com/news/corcept-therapeutics-relacorilant-plus-nab-paclitaxel-shows-positive-results-in-ovarian-cancer/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-22 12:36</span>
                        
                    </div>
                    
                    <p class="news-summary">The PM Awards celebrate creativity in pharmaceutical marketing and healthcare communications</p>
                    
                    <a href="https://pharmatimes.com/news/book-your-tickets-and-join-the-pm-society-for-the-40th-pm-awards-on-20-march-2026/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sun Pharmaâ€™s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-21 12:13</span>
                        
                    </div>
                    
                    <p class="news-summary">More than 71% of patients treated with Unloxcyt achieved disease control</p>
                    
                    <a href="https://pharmatimes.com/news/sun-pharmas-unloxcyt-now-available-in-us-for-advanced-cutaneous-squamous-cell-carcinoma/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Peter Llewellyn-Davies
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-21 12:02</span>
                        
                    </div>
                    
                    <p class="news-summary">ARTCLINE appoints Peter Llewellyn-Davies as Chairman of its Supervisory Board</p>
                    
                    <a href="https://pharmatimes.com/appointments/peter-llewellyn-davies/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
        </main>

        <footer>
            <p>Generated by <strong>Pharma Daily</strong> - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ</p>
            <p>2026-01-28 03:45</p>
        </footer>
    </div>

    <script>
    (function() {
        // ========== Theme Switcher ==========
        const themeBtns = document.querySelectorAll('.theme-btn');
        const savedTheme = localStorage.getItem('pharma-daily-theme') || 'minimal';

        function setTheme(theme) {
            document.body.setAttribute('data-theme', theme);
            themeBtns.forEach(btn => {
                btn.classList.toggle('active', btn.getAttribute('data-theme') === theme);
            });
            localStorage.setItem('pharma-daily-theme', theme);
        }

        // Apply saved theme on load
        setTheme(savedTheme);

        themeBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                setTheme(this.getAttribute('data-theme'));
            });
        });

        // ========== Date Filter ==========
        const filterBtns = document.querySelectorAll('.date-btn');
        const newsCards = document.querySelectorAll('.news-card');
        const filterCount = document.getElementById('filterCount');
        const categories = document.querySelectorAll('.category');

        function updateFilter(selectedDate) {
            let visibleCount = 0;

            newsCards.forEach(card => {
                const cardDate = card.getAttribute('data-date');
                if (selectedDate === 'all' || cardDate === selectedDate) {
                    card.classList.remove('hidden');
                    visibleCount++;
                } else {
                    card.classList.add('hidden');
                }
            });

            // Hide empty categories
            categories.forEach(category => {
                const visibleCards = category.querySelectorAll('.news-card:not(.hidden)');
                category.style.display = visibleCards.length > 0 ? 'block' : 'none';

                // Update category count
                const countSpan = category.querySelector('.category-count');
                if (countSpan) {
                    countSpan.textContent = visibleCards.length + ' æ¡';
                }
            });

            // Update filter count display
            if (selectedDate === 'all') {
                filterCount.textContent = '';
            } else {
                filterCount.textContent = `æ˜¾ç¤º ${visibleCount} æ¡æ–°é—»`;
            }
        }

        filterBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                filterBtns.forEach(b => b.classList.remove('active'));
                this.classList.add('active');
                updateFilter(this.getAttribute('data-filter'));
            });
        });
    })();
    </script>
</body>
</html>